Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 18/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 15/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 14/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4020693 | 0.91 | OPRK1 (0.43) | KCNH2OPRM1OPRK1OPRD1 | |
| SCHEMBL4017382 | 0.91 | OPRK1 (0.42) | KCNH2OPRM1OPRK1OPRD1 | |
| SCHEMBL4019941 | 0.90 | OPRM1 (0.55) | KCNH2OPRM1OPRK1OPRD1 | |
| SCHEMBL4020075 | 0.86 | OPRM1 (0.49) | KCNH2OPRM1OPRK1OPRD1 | |
| SCHEMBL4019178 | 0.86 | OPRK1 (0.44) | KCNH2OPRM1OPRK1OPRD1 | |
| SCHEMBL4021605 | 0.85 | OPRM1 (0.56) | OPRM1OPRK1OPRD1 | |
| SCHEMBL4017784 | 0.85 | OPRK1 (0.44) | KCNH2OPRM1OPRK1OPRD1 | |
| SCHEMBL4016625 | 0.85 | OPRK1 (0.44) | KCNH2OPRM1OPRK1OPRD1 | |
| SCHEMBL4026593 | 0.85 | OPRK1 (0.44) | KCNH2OPRM1OPRK1OPRD1 | |
| SCHEMBL4021261 | 0.85 | OPRM1 (0.48) | KCNH2OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE40838-E1 | 2-azabicyclo[3.3.1]nonane derivatives | PFIZER INC. (US) | 2009-07-07 | — | — | US | claimed |
| US-7056930-B2 | for treatment of disease states, disorders and conditions mediated by opioid receptors; for example, irritable bowel syndrome, drug addiction, including alcohol addiction, depression, anxiety, schizophrenia, eating disorders | PFIZER INC. (US) | 2006-06-06 | — | — | US | claimed |
| US-20040204445-A1 | 2-Azabicyclo[3.3.1]nonane derivatives | PFIZER INC. | 2004-10-14 | — | — | US | claimed |
| EP-1615893-B1 | 2-AZABICYCLO¬3.3.1 NONANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2009-11-18 | — | — | EP | disclosed |
| US-RE40838-E1 | 2-azabicyclo[3.3.1]nonane derivatives | PFIZER INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7056930-B2 | for treatment of disease states, disorders and conditions mediated by opioid receptors; for example, irritable bowel syndrome, drug addiction, including alcohol addiction, depression, anxiety, schizophrenia, eating disorders | PFIZER INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1615893-A1 | 2-AZABICYCLO[3.3.1]NONANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089909-A1 | 2-AZABICYCLO[3.3.1]NONANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204445-A1 | 2-Azabicyclo[3.3.1]nonane derivatives | PFIZER INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204445-A1 | 2-Azabicyclo[3.3.1]nonane derivatives | OPRD1, OPRK1, OPRM1 | KCNH2 1749/4885OPRM1 3/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.